News about "cancer immunotherapy"

NEC, Taiho and Partners Develop Quantum Platform for Cancer Therapy

NEC, Taiho Pharmaceutical and three Japanese research organisations launch a quantum computing project for cancer immunotherapy.

Cancer Immunotherapy | 05/10/2026 | By News Bureau

Daiichi Sankyo Begins Clinical Development of CD25-Targeted ADC DS1025

Daiichi Sankyo advances DS1025 into clinical development as a potential first-in-class CD25-targeted Antibody Drug Conjugate (ADC) for patients with advanced solid tumors.

Cancer Immunotherapy | 01/09/2026 | By News Bureau

Obsidian Enrols First Patient in Pivotal-Pathway Study of Engineered TIL Therapy

The phase 1/2 Agni-01 cohort will evaluate amsoki-cel in ICI-resistant advanced melanoma, with enrollment expected to conclude by Q1 2027 and topline data anticipated by year-end 2027.<br />

Cancer Immunotherapy | 10/08/2026 | By News Bureau |  158

Innovent Doses First Patient in Pivotal IBI363/TAK-928 CRC Study

Innovent has dosed the first patient in its pivotal IBI363/TAK-928 study, advancing next-generation immunotherapy for colorectal cancer.

Cancer Immunotherapy | 06/08/2026 | By News Bureau |  495

Akeso Doses First Patient in Phase 1b/2 Trial of HER3 ADC for Advanced Lung Cancer

Akeso has dosed the first patient in its Phase 1b/2 AK138D1-201 trial, assessing the HER3-targeted antibody-drug conjugate AK138D1 as monotherapy and in combination with ivonescimab for patients with advanced non-small cell lung cancer.

Cancer Immunotherapy | 30/07/2026 | By News Bureau |  181

WuXi Biologics Receives Brazil GMP Certification for Cancer Therapy Manufacturing

WuXi Biologics has received Brazil ANVISA GMP certification with zero inspection findings, enabling global commercial manufacturing of its innovative cancer immunotherapy.

Cancer Immunotherapy | 02/07/2026 | By News Bureau |  115

Ichnos Glenmark Innovation Unveils Novel Multispecific Antibody Candidate for Solid Tumour Treatment

Ichnos Glenmark Innovation has introduced ISB 2301, a next-generation multispecific antibody designed to activate immune cells and target solid tumours through a multi-mechanism approach aimed at improving cancer treatment outcomes.

Cancer Immunotherapy | 22/05/2026 | By News Bureau |  284

Harbour BioMed Secures FDA IND Clearance for HBM7004 in Advanced Solid Tumors

Harbour BioMed receives US Food and Drug Administration (FDA) IND clearance for HBM7004, a novel B7H4xCD3 bispecific antibody developed on its HBICE platform for advanced solid tumors.

Cancer Immunotherapy | 11/05/2026 | By News Bureau |  163

FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy

Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.

Cancer Immunotherapy | 21/04/2026 | By News Bureau |  178

OS Therapies files patent for immune-response biomarker linked to cancer immunotherapy

New data from the Phase IIb trial of OST-HER2 shows distinct immune signatures tied to improved survival outcomes, supporting accelerated approval discussions with global regulators.

Cancer Immunotherapy | 20/04/2026 | By News Bureau |  147